Preparation Of Guideline On ARV Drugs Well Underway

Preparation Of Guideline On ARV Drugs Well Underway

 

   Addis Ababa, August 27, 2001 (WIC) - The National Aids Council Secretariat said

   preparation was well underway to formulate guideline on the proper usage and distribution of

   Antiretroviral (ARV) drugs.

 

   Head of the Secretariat, Dr.Dagnachew Hailemariam told WIC yesterday that the guideline

   that was being prepared by the Ministry of Health would be finalized up until the coming

   November.

 

   He said the guideline would prioritise the availability and affordability of the drugs as well as

   set the rules on administration of the drugs.

 

   Laboratory equipments would be procured to facilitate the monitoring and evaluation of the

   various kinds of the ARVs, he said, adding that training manual for physicians and lab.

   technicians would also be prepared during the stated period.

 

   Dr. Dagnachew underlined the high degree of responsibility on the part of PLWHA not to return

   to risky behaviour as ARVs were meant to reduce the viral load in the body than curing the

   disease.

 

   He said practising safer and protective sex was vital in preventing the spread of HIV/AIDS.

 

   He said the secretariat office had disbursed over 14 million birr to CSOs, NGOs and to National

   States working on HIV/AIDS prevention, care and support as well as research, monitoring and

   evaluation activities.

 

   He said US$ 59 million had been secured from the World Bank in a soft loan for undertaking

   capacity building programmes, emergence AIDS fund and to launch multisectoral as well as

   managing and coordinating campaign against the AIDS pandemic.

 

   He meanwhile said the pilot project that has been launched at Black Lion Hospital to prevent

   mother to child infection of HIV/AIDS would be further expanded at other selected sites

   across the country.

 

   He said the Norwegian Government had pledged to back the effort being deployed to mitigate

   child mortality due to mother to child transmission of HIV/AIDS over the coming five years.